![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ABHD15 |
Gene summary for ABHD15 |
![]() |
Gene information | Species | Human | Gene symbol | ABHD15 | Gene ID | 116236 |
Gene name | abhydrolase domain containing 15 | |
Gene Alias | ABHD15 | |
Cytomap | 17q11.2 | |
Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | Q6UXT9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
116236 | ABHD15 | HCC1_Meng | Human | Liver | HCC | 6.99e-08 | -1.86e-02 | 0.0246 |
116236 | ABHD15 | HCC2_Meng | Human | Liver | HCC | 8.73e-04 | 1.89e-02 | 0.0107 |
116236 | ABHD15 | HCC2 | Human | Liver | HCC | 7.20e-32 | 3.15e+00 | 0.5341 |
116236 | ABHD15 | HCC5 | Human | Liver | HCC | 1.95e-11 | 1.45e+00 | 0.4932 |
116236 | ABHD15 | S014 | Human | Liver | HCC | 7.72e-08 | 3.60e-01 | 0.2254 |
116236 | ABHD15 | S015 | Human | Liver | HCC | 4.89e-07 | 3.84e-01 | 0.2375 |
116236 | ABHD15 | S016 | Human | Liver | HCC | 1.05e-10 | 3.89e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ABHD15 | SNV | Missense_Mutation | rs201924599 | c.1315N>T | p.Arg439Cys | p.R439C | Q6UXT9 | protein_coding | deleterious(0.01) | benign(0) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ABHD15 | SNV | Missense_Mutation | c.920N>C | p.Arg307Thr | p.R307T | Q6UXT9 | protein_coding | tolerated(0.29) | benign(0.009) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
ABHD15 | SNV | Missense_Mutation | novel | c.387G>T | p.Leu129Phe | p.L129F | Q6UXT9 | protein_coding | deleterious(0) | benign(0.437) | TCGA-GM-A3NY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ABHD15 | SNV | Missense_Mutation | novel | c.1106N>G | p.Thr369Ser | p.T369S | Q6UXT9 | protein_coding | tolerated(0.36) | benign(0.034) | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
ABHD15 | SNV | Missense_Mutation | c.706N>C | p.Glu236Gln | p.E236Q | Q6UXT9 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
ABHD15 | SNV | Missense_Mutation | rs371401765 | c.1262N>T | p.Thr421Met | p.T421M | Q6UXT9 | protein_coding | tolerated(0.3) | benign(0) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ABHD15 | SNV | Missense_Mutation | c.1046C>T | p.Ala349Val | p.A349V | Q6UXT9 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ABHD15 | SNV | Missense_Mutation | rs776728486 | c.1036G>A | p.Asp346Asn | p.D346N | Q6UXT9 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-F4-6856-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Ancillary | leucovorin | CR |
ABHD15 | SNV | Missense_Mutation | rs145964335 | c.1022C>T | p.Pro341Leu | p.P341L | Q6UXT9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A1DO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ABHD15 | SNV | Missense_Mutation | novel | c.1210N>G | p.Ser404Gly | p.S404G | Q6UXT9 | protein_coding | tolerated(0.1) | benign(0.145) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |